{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:37:11Z","timestamp":1790390231575,"version":"4.1.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T00:00:00Z","timestamp":1338249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0001544","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T17:18:45Z","timestamp":1338311925000},"page":"e1544","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal"],"prefix":"10.1371","volume":"6","author":[{"given":"Thomas P. C.","family":"Dorlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teunis A.","family":"Eggelte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard J.","family":"Schoone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,5,29]]},"reference":[{"key":"ref1","first-page":"281","article-title":"History of kala-azar in India.","volume":"82","author":"PC Sengupta","year":"1947","journal-title":"Indian Med Gaz"},{"key":"ref2","first-page":"394","article-title":"Availability of miltefosine for the treatment of kala-azar in India.","volume":"83","author":"S Sundar","year":"2005","journal-title":"Bull World Health Organ"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-3156.2009.02279.x","article-title":"The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India.","volume":"14","author":"M Boelaert","year":"2009","journal-title":"Trop Med Int Health"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","article-title":"Leishmaniasis impact and treatment access.","volume":"17","author":"M den Boer","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis.","volume":"100","author":"H Sindermann","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1371\/journal.pntd.0000818","article-title":"Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent.","volume":"4","author":"F Meheus","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-3156.2006.01782.x","article-title":"Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.","volume":"12","author":"V Vanlerberghe","year":"2007","journal-title":"Trop Med Int Health"},{"key":"ref8","article-title":"Programme manager's meeting on elimination of Kala-azar in the South-East Asia Region, Faridabad, Haryana, India, 17\u201319 February 2009.","year":"2010"},{"key":"ref9","article-title":"WHO Technical Report Series 949: Annex 6 - Costs of medicines in current use for the treatment of leishmaniasis.","year":"2010"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S1473-3099(08)70241-X","article-title":"Global health-care implications of substandard medicines.","volume":"8","author":"K Senior","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1039\/c2an15641e","article-title":"Characterization and identification of suspected counterfeit miltefosine capsules.","volume":"137","author":"TPC Dorlo","year":"2012","journal-title":"Analyst"},{"key":"ref12","first-page":"195","article-title":"Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable.","volume":"123","author":"SK Bhattacharya","year":"2006","journal-title":"Indian J Med Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-3156.2007.01974.x","article-title":"Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal\u2013the challenges for diagnosis and treatment.","volume":"13","author":"S Sundar","year":"2008","journal-title":"Trop Med Int Health"},{"key":"ref14","article-title":"Regional Technical Advisory Group on Kala-azar Elimination - Report of the Second Meeting, Kathmandu, Nepal, 30 October\u20132 November 2006.","year":"2007"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.","volume":"196","author":"SK Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jchromb.2008.02.005","article-title":"Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.","volume":"865","author":"TPC Dorlo","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref17","article-title":"Impavido 10\/50 mg Kapseln- Fachinformation.","year":"2008"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.00014-08","article-title":"Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.","volume":"52","author":"TPC Dorlo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/JCM.01416-07","article-title":"Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites.","volume":"46","author":"W van der Meide","year":"2008","journal-title":"J Clin Microbiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0035-9203(00)90055-5","article-title":"Visceral leishmaniasis control: a public health perspective.","volume":"94","author":"M Boelaert","year":"2000","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.cimid.2004.03.004","article-title":"Leishmaniasis: current situation and new perspectives.","volume":"27","author":"P Desjeux","year":"2004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tips.2009.11.005","article-title":"Impact of poor-quality medicines in the \u201cdeveloping\u201d world.","volume":"31","author":"PN Newton","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e1000052","DOI":"10.1371\/journal.pmed.1000052","article-title":"Guidelines for field surveys of the quality of medicines: a proposal.","volume":"6","author":"PN Newton","year":"2009","journal-title":"PLoS Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1039\/C0AN00627K","article-title":"Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries.","volume":"136","author":"FM Fernandez","year":"2011","journal-title":"Analyst"},{"key":"ref25","article-title":"Counterfeit & substandard drugs - Frequently asked questions.","year":"2005"},{"key":"ref26","article-title":"What are substandard medicines?","year":"2009"},{"key":"ref27","article-title":"New definition for \u201csubstandard medicines\u201d.","year":"2010"},{"key":"ref28","article-title":"Counterfeit medical products.","year":"2008"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4269\/ajtmh.1998.59.139","article-title":"A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate.","volume":"59","author":"S Sundar","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0035-9203(03)80043-3","article-title":"Sodium stibogluconate cardiotoxicity and safety of generics.","volume":"97","author":"S Rijal","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1046\/j.1365-3156.2002.00959.x","article-title":"How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis.","volume":"7","author":"M Boelaert","year":"2002","journal-title":"Trop Med Int Health"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1473-3099(06)70581-3","article-title":"Counterfeit anti-infective drugs.","volume":"6","author":"PN Newton","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3201\/eid1511.090886","article-title":"Epidemic of Plasmodium falciparum Malaria Involving Substandard Antimalarial Drugs, Pakistan, 2003.","volume":"15","author":"T Leslie","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1365-3156.2008.02106.x","article-title":"Substandard medicines in resource-poor settings: a problem that can no longer be ignored.","volume":"13","author":"J-M Caudron","year":"2008","journal-title":"Trop Med Int Health"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1371\/journal.pmed.0050032","article-title":"A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia.","volume":"5","author":"PN Newton","year":"2008","journal-title":"PLoS Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(03)13872-X","article-title":"Counterfeit artesunate antimalarials in southeast Asia.","volume":"362","author":"PN Newton","year":"2003","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1365-3156.2004.01342.x","article-title":"Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials.","volume":"9","author":"AM Dondorp","year":"2004","journal-title":"Trop Med Int Health"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e1001139","DOI":"10.1371\/journal.pmed.1001139","article-title":"The primacy of public health considerations in defining poor quality medicines.","volume":"8","author":"PN Newton","year":"2011","journal-title":"PLoS Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1473-3099(09)70090-8","article-title":"Poor-quality medicines in developing countries.","volume":"9","author":"RM Ravinetto","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"ref40","article-title":"WHO Technical Report Series 961: WHO Expert Committee on Specifications for Pharmaceutical Preparations, Forty-fifth Report.","year":"2011"},{"key":"ref41","article-title":"Prequalification of Medicines Programme - a United Nations programme managed by the WHO.","year":"2010"},{"key":"ref42","article-title":"17th WHO Model List of Essential Medicines.","year":"2011"},{"key":"ref43","article-title":"Application for inclusion of miltefosine on WHO Model List of Essential Medicines.","year":"2010"},{"key":"ref44","article-title":"Directorate General of Drug Administration website.","year":"2011"}],"container-title":["PLoS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0001544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T23:43:34Z","timestamp":1540251814000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0001544"}},"subtitle":[],"editor":[{"given":"Marleen","family":"Boelaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,5,29]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0001544","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.720295206.793549590","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,29]]}}}